1. Protective Effect of Baicalein on oxLDL-induced Oxidative Stress and Inflammation Injury in Endothelial Cell
   Changjiang Du et al, 2017, International J. of Pharmacology CrossRef
2. Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
   Simon Glerup et al, 2017, Basic Res Cardiol CrossRef
3. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
   Yan Zhang et al, 2014, Journal of Clinical Lipidology CrossRef
4. LDL apheresis in Japan
   Hisashi Makino et al, 2017, Transfusion and Apheresis Science CrossRef
5. The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer’s disease progression (Review)
   QI WU et al, 2014 CrossRef
6. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9
   Sha Li et al, 2015, Nutrition, Metabolism and Cardiovascular Diseases CrossRef
7. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
   Sha Li et al, 2014, Atherosclerosis CrossRef
8. Imbalanced cholesterol metabolism in Alzheimer's disease
   Zhao Xue-shan et al, 2016, Clinica Chimica Acta CrossRef
9. Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way
   Klaus-Dieter Schlüter et al, 2017, Basic Res Cardiol CrossRef
10. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure
    Antoni Bayes-Genis et al, 2017, Journal of the American College of Cardiology CrossRef
11. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV
    Markella V Zanni et al, 2017 CrossRef
12. PCSK9 signaling pathways and their potential importance in clinical practice
    Michał Wiciński et al, 2017, EPMA Journal CrossRef
13. High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk
    Chengfeng Qiu et al, 2017, Medicine CrossRef
14. Hypothesis
    Wenguang Wang et al, 2017, J Cardiovasc Pharmacol Ther CrossRef
15. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
    Zhi-Han Tang et al, 2017, Atherosclerosis CrossRef
16. Propofol selectively inhibits nuclear factor-κB activity by suppressing p38 mitogen-activated protein kinase signaling in human EA.hy926 endothelial cells during intermittent hypoxia/reoxygenation
    DONGLIANG LI et al, 2014 CrossRef
17. Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population.
    Wen Guo et al, 2018, Lipids Health Dis CrossRef
18. PCSK9 induces a pro-inflammatory response in macrophages
    Chiara Ricci et al, 2018, Sci Rep CrossRef
19. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia
    Yu Kataoka et al, 2017, Journal of Clinical Lipidology CrossRef
20. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation
    Angelos D. Karagiannis et al, 2018, Curr Atheroscler Rep CrossRef
21. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
    Sophie J. Bernelot Moens et al, 2017 CrossRef
22. PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
    Xue-qin Bai et al, 2018, Clinica Chimica Acta CrossRef
23. Role of PCSK9 in lipid metabolism and atherosclerosis
    Xiao-Long Lin et al, 2018, Biomedicine & Pharmacotherapy CrossRef
24. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
    Jin M. Cheng et al, 2016, Atherosclerosis CrossRef
25. PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
    Massimo R. Mannarino et al, 2018, Journal of Clinical Lipidology CrossRef
26. Naringin activates AMPK resulting in altered expression of SREBPs, PCSK9, and LDLR to reduce body weight in obese C57BL/6J mice
    GUO-GUANG SUI et al, 2018, J. Agric. Food Chem. CrossRef
27. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells
    Ting‐Hsing Chao et al, 2016, J Am Heart Assoc CrossRef
28. PCSK9: A novel inflammation modulator in atherosclerosis?
    Zhi-Han Tang et al, 2018, J Cell Physiol CrossRef
29. Induction of Sustained Hypercholesterolemia by Single Adeno-Associated Virus–Mediated Gene Transfer of Mutant hPCSK9
    Marta Roche-Molina et al, 2015, Arterioscler Thromb Vasc Biol. CrossRef
30. Inhibiting PCSK9 — biology beyond LDL control
    Robert M. Stoekenbroek et al, 2018, Nat Rev Endocrinol CrossRef
31. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial
    Konstantinos C. Koskinas et al, 2018, Clin Cardiol CrossRef
32. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology
    José Tuñón et al, 2018 CrossRef
33. Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation
    Nattayaporn Apaijai et al, 2019, J Am Heart Assoc CrossRef
34. Potentiation of Psoriasis-Like Inflammation by PCSK9
    Chao Luan et al, 2018, Journal of Investigative Dermatology CrossRef
35. Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation
    Michael Kühl et al, 2019, PLoS ONE CrossRef
36. Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines
    Dragan B. Djordjevic et al, 2019, Curr Pharmacol Rep CrossRef
37. Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction
    Zhong Zhang et al, 2019, Sci Rep CrossRef
38. Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
    Ni-ya He et al, 2017, Acta Pharmacol Sin CrossRef
39. Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome
    Nutjaree Jeenduang, 2019, Clinica Chimica Acta CrossRef
40. Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics
    Dong An et al, 2015, Sci Rep CrossRef
41. Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality
    Gang Wang et al, 2019, BioMed Research International CrossRef
42. 冠動脈疾患を有する家族性高コレステロール血症の血液中proprotein convertase subtilisin/kexin 9の意義
    , 2016, Journal of JCS Cardiologists CrossRef
43. Familial Hypercholesterolemia and Lipoprotein Apheresis
    Hisashi Makino et al, 2019, JAT CrossRef
44. PCSK9 and inflammation: a review of experimental and clinical evidence
    Amir Abbas Momtazi-Borojeni et al, 2019 CrossRef
45. The Expression of Inflammatory Cytokines on the Aorta Endothelia Are Up-regulated in Pinealectomized Rats
    Yu Wang et al, 2013, Inflammation CrossRef
46. Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
    Daniel Urban et al, 2013, Journal of the American College of Cardiology CrossRef
47. Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
    Thor Ueland et al, 2018, Open Heart CrossRef
48. The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
    Sha Li et al, 2015, J Atheroscler Thromb CrossRef
49. PCSK9 and its modulation
    Chuan-Jue Cui et al, 2015, Clinica Chimica Acta CrossRef
50. PCSK9: A key factor modulating atherosclerosis
    Sha Li et al, 2015, J Atheroscler Thromb CrossRef
51. Perspektiven zu cholesterinwirksamer Behandlung 2014
    Gerald Klose et al, 2014, CV CrossRef
52. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Rainer Schulz et al, 2015, Basic Res Cardiol CrossRef
53. Atherosclerosis: Recent trials, new targets and future directions
    Ricardo Ladeiras-Lopes et al, 2015, International Journal of Cardiology CrossRef
54. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Lingling Zhang et al, 2015, International Journal of Neuroscience CrossRef
55. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
    Sha Li et al, 2015, Annals of Medicine CrossRef
56. Local effects of human PCSK9 on the atherosclerotic lesion
    Ilaria Giunzioni et al, 2016, J. Pathol. CrossRef
57. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
    GPS Shantha et al, 2016, Clin. Pharmacol. Ther. CrossRef
58. Macrophage-mediated cholesterol handling in atherosclerosis.
    Dimitry A Chistiakov et al, 2016, J Cell Mol Med CrossRef
59. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications
    Eliano P. Navarese et al, 2016, Eur Heart J Cardiovasc Pharmacother CrossRef
60. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
    Hagai Tavori et al, 2016, Cardiovasc Res CrossRef
61. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
    Giuseppe Danilo Norata et al, 2016, Cardiovasc Res CrossRef
62. The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants
    AnneMarie Gagnon et al, 2016, Obesity CrossRef
63. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Tsuyoshi Nozue et al, 2016, Lipids Health Dis CrossRef
64. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
    Maria Pia Adorni et al, 2017, Atherosclerosis CrossRef
65. Macrophage Apoptosis and Necrotic Core Development in Atherosclerosis: A Rapidly Advancing Field with Clinical Relevance to Imaging and Therapy.
    Leticia Gonzalez et al, 2017, Can J Cardiol CrossRef
66. PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway
    Lu-Shan Liu et al, 2017, JAD CrossRef
67. Hypercholesterolemia: The role of PCSK9
    Quantil M. Melendez et al, 2017, Archives of Biochemistry and Biophysics CrossRef
68. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data
    Ashwin Durairaj et al, 2017, Curr Treat Options Cardio Med CrossRef
69. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
    Ye-Xuan Cao et al, 2019, J Transl Med CrossRef
70. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
    Bo Chen et al, 2019, CTMC CrossRef
71. Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
    Gema Miñana et al, 2020, ESC Heart Failure CrossRef
72. Lowering inflammation through lipid-lowering therapy: are we there yet?
    Nayan Agarwal et al, 2020 CrossRef
73. Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?
    Rana Shafabakhsh et al, 2020, Critical Reviews in Food Science and Nutrition CrossRef
74. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes
    Ying Tang et al, 2020, Cardiovasc Diabetol CrossRef
75. Naturally Occurring PCSK9 Inhibitors
    Maria Pia Adorni et al, 2020, Nutrients CrossRef
76. PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
    Elena Dozio et al, 2020, Mediators of Inflammation CrossRef
77. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
    Anders Hovland et al, 2020, Scandinavian Cardiovascular Journal CrossRef
78. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
    Kyung Hoon Cho et al, 2020, Korean J Intern Med CrossRef
79. Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall
    Yanan Guo et al, 2020, J Cell Physiol CrossRef
80. PCSK9: A Potential Therapeutic Target for Sepsis
    Yuan Yuan et al, 2020, Journal of Immunology Research CrossRef
81. PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
    Ioanna Andreadou et al, 2020, Front. Physiol. CrossRef
82. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
    Masato Furuhashi et al, 2020, JAT CrossRef
83. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
    Ga Eun Lee et al, 2021, Front. Endocrinol. CrossRef
84. HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis
    Sally A. Abuelezz et al, 2021, Life Sciences CrossRef
85. Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease
    Konstantin A. Krychtiuk et al, 2021, Journal of Clinical Lipidology CrossRef
86. Pleiotropic Effects of PCSK-9 Inhibitors
    Marcin Basiak et al, 2021, IJMS CrossRef
87. PCSK9 and LRP5 in macrophage lipid internalization and inflammation.
    Lina Badimon et al, 2021, Cardiovasc Res CrossRef
88. Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
    Piotr Pęczek et al, 2021, Life CrossRef
89. Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via LDLR
    L. Huang et al, 2021, J Dent Res CrossRef
90. Prognostic Value of PCSK9 Levels in Non-ST elevation myocardial infarction Patients Undergoing Percutaneous Coronary Intervention (PCI)
    Jixiang Wang et al, 2021, Hellenic Journal of Cardiology CrossRef
91. Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
    Sylwester Rogula et al, 2021, JCM CrossRef
92. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
    Anindita Bhattacharya et al, 2021, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
93. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients
    Evangelia Dounousi et al, 2021, Oxidative Medicine and Cellular Longevity CrossRef
94. Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
    Ping Jin et al, 2021, Front. Cardiovasc. Med. CrossRef
95. PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
    Aikaterini Arida et al, 2021, Front. Cardiovasc. Med. CrossRef
96. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI
    Xiaoxiao Zhao et al, 2021, JIR CrossRef
97. Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort
    Yan Gao et al, 2018, Cardiology CrossRef
98. The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2
    Suan-Sin Foo et al, 2021, Cell Reports Medicine CrossRef
99. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
    Patrice Marques et al, 2022, Biomedicine & Pharmacotherapy CrossRef
100. Rotigotine protects against oxidized low-density lipoprotein(ox-LDL)-induced damages in human umbilical vein endothelial cells(HUVECs)
     Hui Kang et al, 2021, Bioengineered CrossRef
101. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
     Emily Punch et al, 2022, JAHA CrossRef
102. Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
     Na-Qiong Wu et al, 2022, Front. Cardiovasc. Med. CrossRef
103. Insight into the Evolving Role of PCSK9
     Mateusz Maligłówka et al, 2022, Metabolites CrossRef
104. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
     Huimin Sun et al, 2022, Naunyn-Schmiedeberg's Arch Pharmacol CrossRef
105. Protective Mechanism of Proprotein Convertase Subtilisin-Like Kexin Type 9 Inhibitor on Rats with Middle Cerebral Artery Occlusion-Induced Cerebral Ischemic Infarction
     Shengxiong Pu et al, 2022, Computational Intelligence and Neuroscience CrossRef
106. The R93C Variant of PCSK9 Reduces the Risk of Premature MI in a Chinese Han Population
     Lincheng Yang et al, 2022, Front. Genet. CrossRef
107. New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
     Achim Leo Burger et al, 2022, Biomedicines CrossRef
108. Mechanisms and Drug Therapies of Bioprosthetic Heart Valve Calcification
     Shuyu Wen et al, 2022, Front. Pharmacol. CrossRef
109. PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery
     Silvia Ortona et al, 2022, JCM CrossRef
110. PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
     Baris Gencer et al, 2022, CMC CrossRef
111. Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
     Nabil G. Seidah et al, 2022, Curr Atheroscler Rep CrossRef
112. Serum cholesterol loading capacity of macrophages is regulated by seropositivity and C-reactive protein in rheumatoid arthritis patients
     George A Karpouzas et al, 2022 CrossRef
113. Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction
     Paolo Cimaglia et al, 2022, Nutrition, Metabolism and Cardiovascular Diseases CrossRef
114. LDL oxydées et récepteur des LDL oxydées associés à la proprotéine-convertase-subtilisine/kexine type 9 chez des patients avec diabète de type 2
     Ymène Nekaies et al, 2022, Revue Francophone des Laboratoires CrossRef
115. Genotype‐driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis
     Sebastian‐Edgar Baumeister et al, 2022, J Clinic Periodontology CrossRef
116. The relationship between pulse pressure with plasma PCSK9 and interleukin-6 among patients with acute ischemic stroke and dyslipidemia
     Chen-Shu Chang et al, 2022, Brain Research CrossRef
117. The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction
     Jun Sawaguchi et al, 2022, Atherosclerosis Plus CrossRef
118. Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial
     Masaharu Ishihara et al, 2022 CrossRef
119. PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells
     Maria Francesca Greco et al, 2022, IJMS CrossRef
120. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms
     Shunsuke Katsuki et al, 2022, Circ Res CrossRef
121. Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome
     F. B. Mensink et al, 2022, Front. Cardiovasc. Med. CrossRef
122. PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
     Malak Alannan et al, 2022, Cells CrossRef
123. Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis
     Christin G. Hong et al, 2023, Front. Cardiovasc. Med. CrossRef
124. PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
     Pere Rehues et al, 2023, IJMS CrossRef